Fairmount Funds Management LLC Astria Therapeutics, Inc. Transaction History
Fairmount Funds Management LLC
- $498 Million
- Q4 2024
A detailed history of Fairmount Funds Management LLC transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Fairmount Funds Management LLC holds 3,554,129 shares of ATXS stock, worth $25 Million. This represents 6.29% of its overall portfolio holdings.
Number of Shares
3,554,129
Previous 3,554,129
-0.0%
Holding current value
$25 Million
Previous $39.1 Million
19.98%
% of portfolio
6.29%
Previous 6.36%
Shares
3 transactions
Others Institutions Holding ATXS
# of Institutions
115Shares Held
50.3MCall Options Held
75KPut Options Held
6.2K-
Perceptive Advisors LLC New York, NY6.49MShares$45.6 Million1.91% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.11MShares$35.9 Million0.73% of portfolio
-
Vestal Point Capital, LP New York, NY4.18MShares$29.4 Million2.22% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$24.7 Million0.0% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.87MShares$20.2 Million4.34% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $107M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...